BIO

Rachel Abbott joined Pan Cancer T as CSO in January 2023 and became CEO in May 2023. With over a decade of industry experience developing T cell therapies for cancer, Rachel has led research teams and managed collaborations with big pharma and academia. Rachel was Senior Director at Enara Bio for two years, overseeing the TCR Pipeline and Dark Antigen Research. She spent over six years at Adaptimmune, progressing from Senior Scientist to Head of Pipeline Cell Biology. Previously, she was a Research Fellow at the University of Birmingham. Rachel holds a DPhil and an MBiochem from the University of Oxford.